This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kimura, B. Articles by Phillips, M. I. Search for Related Content PubMed PubMed Citation Articles by Kimura, B. Articles by Phillips, M. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Genes and Gene Therapy High Blood Pressure Related Collections Other hypertension Gene therapy

(Hypertension. 2001;37:376.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Attenuation of Hypertension and Heart Hypertrophy by Adeno-Associated Virus Delivering Angiotensinogen Antisense

Birgitta Kimura; Dagmara Mohuczy; Xiaoping Tang; M. Ian Phillips

From the Department of Physiology, University of Florida (B.K., D.M., X.T., M.I.P.), Gainsville.

Correspondence to M. Ian Phillips, PhD, DSc, Department of Physiology, University of Florida, 1600 SW Archer Rd, PO Box 100274, Gainsville, FL 32608. E-mail MIP{at}phys.med.ufl.edu

Angiotensinogen (AGT), one of the major components in the renin-angiotensin system, has been linked to hypertension in humans and animals. We have previously systemically administered antisense oligonucleotides and plasmid vectors with DNA that targeted AGT and attenuated hypertension in spontaneously hypertensive rats. The aim of the present study was to prolong the effect of antisense treatment by the use of a recombinant adeno-associated viral (rAAV) vector targeted to AGT. Using a model of lifelong hypertension in which 5-day-old spontaneously hypertensive rats are treated, a single intracardiac injection of rAAV-AGT-antisense (rAAV-AGT-AS) delayed the onset of hypertension for 91 days and significantly attenuated hypertension in adulthood for up to 6 months. Systolic blood pressure was always lower, by up to 23 mm Hg in the AS-treated group. The vector was stable and expressed a reporter gene in liver, kidney, and heart. The rAAV-AGT-AS treatment significantly decreased left ventricular hypertrophy (P=0.01) and also lowered levels of AGT in the liver (2.78±0.61 µg/g tissue versus 5.23±0.41 µg/g tissue for the sense-treated group, P<0.01). Measurement of liver transaminases showed no evidence for liver toxicity. We conclude that rAAV-AGT-AS offers a safe, stable approach for gene therapy of hypertension.

Key Words: adeno-associated virus • hypertrophy, cardiac • antisense • gene therapy • angiotensinogen

This article has been cited by other articles:

				M. K. Raizada and S. D. Sarkissian Potential of Gene Therapy Strategy for the Treatment of Hypertension Hypertension, January 1, 2006; 47(1): 6 - 9. [Full Text] [PDF]

				L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]

				H. Wang, S. Gallinat, H.-w. Li, C. Sumners, M. K. Raizada, and M. J. Katovich Elevated blood pressure in normotensive rats produced by 'knockdown' of the angiotensin type 2 receptor Exp Physiol, May 1, 2004; 89(3): 313 - 322. [Abstract] [Full Text] [PDF]

				D. Chu, C. C. Sullivan, M. D. Weitzman, L. Du, P. L. Wolf, S. W. Jamieson, and P. A. Thistlethwaite Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 671 - 679. [Abstract] [Full Text] [PDF]

				P. Sinnayah, T. E. Lindley, P. D. Staber, M. D. Cassell, B. L. Davidson, and R. L. Davisson Selective Gene Transfer to Key Cardiovascular Regions of the Brain: Comparison of Two Viral Vector Systems Hypertension, February 1, 2002; 39(2): 603 - 608. [Abstract] [Full Text] [PDF]

				M. I. Phillips Gene Therapy for Hypertension: The Preclinical Data Hypertension, September 1, 2001; 38(3): 543 - 548. [Abstract] [Full Text] [PDF]